• Triacetin: From Metabolism to Translational Strategy

  2026-09-21

  Triacetin, or glyceryl triacetate, is more than a formulation excipient: it is a metabolically active research reagent that connects acetate biology, AMPK signaling, lipid regulation, HDAC-associated mechanisms, and apoptosis studies. This article places APExBIO BA1710 in a translational framework and distinguishes established evidence from exploratory opportunities in glioblastoma, metabolic research, ocular formulation, and immuno-oncology.

• Bortezomib (PS-341): From Inhibition to Translation

  2026-09-21

  Bortezomib (PS-341) is more than a potent 20S proteasome inhibitor: it is a translational probe for separating growth arrest from cell death. This article connects mechanism, assay design, formulation, model selection, and clinical relevance to help researchers build more predictive cancer studies.

• NLRP10, Keratinocyte Survival, and AD Barrier Function

  2026-09-20

  The 2024 reference study defines NLRP10 as an epidermal homeostasis regulator that links keratinocyte survival to P63-dependent differentiation and barrier integrity. Using atopic dermatitis samples and an air-lift human skin equivalent, the authors connect reduced NLRP10 with caspase-8 activation and defective epidermal maturation, providing a mechanistic framework for interpreting NLRP10-associated disease risk.

• Fenofibrate, PPARα–YAP Signaling, and Liver Aging

  2026-09-19

  The reference study shows that fenofibrate-induced liver enlargement and activation of the PPARα–YAP signaling axis are preserved across multiple aging mouse models. Its findings suggest that aging does not substantially eliminate this hepatic response, while also defining useful experimental endpoints for lipid metabolism research and studies of liver growth.

• Acifran Workflows for HCAR2/HCAR3 Research

  2026-09-18

  Acifran enables controlled HCAR2/GPR109A and HCAR3/GPR109B agonism for cAMP, receptor pharmacology, and lipid metabolism workflows. Structure-guided pairing of receptor assays with careful compound handling helps distinguish ligand response from solubility, expression, and assay-window artifacts.

• Protein A/G Magnetic Co-IP/IP Kit for IVDD

  2026-09-18

  Learn how the Protein A/G Magnetic Co-IP/IP Kit can translate BATF2-ATF3 findings into rigorous protein-complex experiments in intervertebral disc degeneration. This guide connects magnetic immunoprecipitation design with mitochondrial biology, controls, workflow choices, and interpretation limits.

• LY2886721: From BACE1 Potency to Assay Design

  2026-09-17

  LY2886721 is a BACE inhibitor suited to mechanistic Alzheimer’s disease research. This article explains how to connect biochemical potency, APP-processing biomarkers, amyloid beta reduction, and synaptic readouts into a better experimental design.

• TCAIM–OGDH Control of Mitochondrial Metabolism

  2026-09-17

  The 2025 Molecular Cell study identifies TCAIM as a mitochondrial DNAJC co-chaperone that selectively binds native OGDH and lowers its abundance through an HSPA9- and LONP1-dependent process. The findings establish mitochondrial proteostasis as an active regulator of metabolic enzyme levels, OGDH complex activity, and carbohydrate catabolism in cells and mice.

• Berberrubine chloride Research Workflows

  2026-09-16

  Build mechanism-led workflows around Berberrubine chloride for colorectal cancer, NSCLC chemosensitivity, hyperuricemia, and enzyme-mediated drug-interaction studies. The platform combines DMSO-compatible formulation, multi-target biology, and a newly defined mechanism-based CYP2D6 inactivation workflow.

• Ampicillin sodium for Selection and Assay Workflows

  2026-09-16

  Ampicillin sodium supports two complementary research needs: plasmid selection during recombinant protein production and controlled β-lactam exposure in antibacterial activity assays. This guide connects those use cases with a reference-based annexin V workflow, practical protocol parameters, and troubleshooting strategies for reproducible results.

• FITC-Concanavalin A (ConA) Conjugate Guide

  2026-09-15

  FITC-Concanavalin A (ConA) Conjugate is a fluorescent lectin reagent for detecting α-D-glucose and α-D-mannose residues on glycoproteins and glycolipids in cell or tissue samples. It supports immunofluorescence staining and flow cytometry carbohydrate analysis, but it should not be treated as a general glycan stain, an antibody substitute, or a probe for non-carbohydrate targets.

• FLOT1–FOSL2–EphA2 Axis in AD Neuroinflammation

  2026-09-15

  A 2026 Neuropharmacology study identifies a FLOT1–FOSL2–EphA2 regulatory axis that promotes pro-inflammatory microglial polarization through p38/MAPK signaling in an APP/PS1 model. By combining molecular interaction assays with behavioral testing, the work connects a defined transcriptional mechanism to neuroinflammation and impaired spatial memory, while also clarifying how the pathway might be examined in complementary cell-based systems.

• BCA Protein Quantification Kit K4102 Guide

  2026-09-14

  The Bicinchoninic Acid Assay (BCA) Protein Quantification Kit K4102 supports total-protein measurement in dilute samples, including many detergent-containing preparations and cell lysates. It is intended for scientific research workflows such as sample normalization and is not for diagnostic, clinical, or medical testing.

• BCA Protein Quantification Kit: K4102 Guide

  2026-09-14

  The Bicinchoninic Acid Assay (BCA) Protein Quantification Kit K4102 supports sensitive total-protein measurement in dilute samples, including many detergent-containing preparations and cell lysates. It is intended for scientific research workflows such as sample normalization and is not validated for diagnostic, clinical, or medical use.

• Açaí Extracts in Human Hepatocytes: Key Findings

  2026-09-13

  Raichura and colleagues combined cytotoxicity testing, hepatocyte gene-expression analysis, and complementary transporter assays to evaluate whether consumer-relevant açaí extracts alter pharmacokinetic pathways. The study found extract-specific, dose- and time-dependent loss of hepatocyte viability but little evidence of CYP or transporter induction, supporting more disciplined evaluation of botanical–drug interaction risk.

7967 records 1/532 page Next 12345 下5页 Last page